Amycretin
Amycretin, a unimolecular GLP-1 and amylin receptor agonist
N/A Amino Acids · MW: N/A
Amino Acids
N/A
Molecular Weight
N/A
Half-life
long-acting; exact half-life not publicly standardized
Research Score
4.6
Studies
9
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Amycretin?
Amycretin is a novel dual-acting peptide designed to combine GLP-1 receptor agonism with amylin receptor signaling in a single molecule. It is being explored as a higher-potency obesity therapy with both oral and subcutaneous development paths.
Key Benefits & Mechanisms
weight loss
appetite suppression
potential oral administration
improved glycemic control
Research Summary
Preliminary human data indicate substantial body-weight reduction at relatively early development stages, generating strong interest in dual incretin/amylin mechanisms. Ongoing research is evaluating formulation, dose optimization, and durability of response.
Related Peptides
RgIA
alpha-Conotoxin RgIA from Conus regius venom
RgIA is a disulfide-rich cone snail peptide that selectively antagonizes the alpha9alpha10 nicotinic acetylcholine receptor. It is used as a research tool in pain and neuroimmune signaling studies and as a pre-clinical analgesic lead.
ExperimentalConantokin-G
Conantokin-G from Conus geographus venom
Conantokin-G is a gamma-carboxyglutamate-rich cone snail peptide that antagonizes NMDA receptor activity. It has been used extensively to study excitatory neurotransmission and seizure biology.
ExperimentalMambalgin-1
Mambalgin-1 from Dendroaspis polylepis venom
Mambalgin-1 is a three-finger snake venom peptide that inhibits acid-sensing ion channels (ASICs), especially ASIC1a and ASIC1b. It is studied as a non-opioid analgesic lead with strong mechanistic value in sensory neuroscience.
ExperimentalHuwentoxin-IV
Huwentoxin-IV from Selenocosmia huwena venom
Huwentoxin-IV is a spider venom peptide that potently targets voltage-gated sodium channels, with strong interest around Nav1.7. It is widely used as a tool compound for ion-channel pharmacology and analgesic discovery.
Experimental